ADMP - Adamis Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0500
-0.0100 (-0.94%)
As of 9:38AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.0600
Open1.0500
Bid1.0500 x 21500
Ask1.1500 x 3000
Day's Range1.0400 - 1.0500
52 Week Range0.9300 - 4.2500
Volume33,935
Avg. Volume476,082
Market Cap64.51M
Beta (3Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-0.8310
Earnings DateNov 7, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.37
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents

    Edited Transcript of ADMP earnings conference call or presentation 8-Aug-19 9:00pm GMT

    Q2 2019 Adamis Pharmaceuticals Corp Earnings Call

  • GlobeNewswire

    Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding Subsidiary

    Ulcers are common in the majority of horses that are subject to stress and can affect horses at any age.  Examples of horses under stress include racehorses, endurance horses, dressage horses, hunters, jumpers, 3-day eventers and any type of rodeo horse.  In general, horses that are in active training tend to have a prevalence of ulcers in the range of 90 to 95%.  Historically, ulcers have been known to negatively affect feeding habits and performance on the track.

  • Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates

    Adamis (ADMP) delivered earnings and revenue surprises of -33.33% and -1.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Adamis Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update

    SAN DIEGO, Aug. 08, 2019 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2019 and provided a.

  • Did Changing Sentiment Drive Adamis Pharmaceuticals's (NASDAQ:ADMP) Share Price Down A Painful 73%?
    Simply Wall St.

    Did Changing Sentiment Drive Adamis Pharmaceuticals's (NASDAQ:ADMP) Share Price Down A Painful 73%?

    Even the best investor on earth makes unsuccessful investments. But it would be foolish to simply accept every...

  • GlobeNewswire

    Adamis Pharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update

    SAN DIEGO, Aug. 05, 2019 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”), a specialty biopharmaceutical company primarily focused on developing and.

  • Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
    Zacks

    Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants

    Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose, announced today the pricing of its previously announced underwritten public offering of 12,000,000 shares of its common stock and warrants to purchase up to 12,000,000 shares of its common stock. Each share of common stock is being sold together with a warrant to purchase one share of common stock for a combined public offering price of $1.00, resulting in gross proceeds of approximately $12,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the company and excluding the proceeds from the exercise of any warrants.

  • GlobeNewswire

    Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants

    Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose, announced today that it intends to offer to sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The company expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock and/or warrants to purchase shares of its common stock offered in the public offering.

  • Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings?
    Zacks

    Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings?

    ABIOMED's (ABMD) flagship Impella receives a slew of regulatory approvals.

  • Masimo (MASI) to Report Q2 Earnings: What's in the Offing?
    Zacks

    Masimo (MASI) to Report Q2 Earnings: What's in the Offing?

    Masimo's (MASI) recent developments likely to show on second-quarter results.

  • What's in the Offing for DexCom's (DXCM) Earnings in Q2?
    Zacks

    What's in the Offing for DexCom's (DXCM) Earnings in Q2?

    Top-line growth and rising global awareness of the company's real-time CGM are likely to aid DexCom's (DXCM) Q2 earnings.

  • GlobeNewswire

    Adamis Pharmaceuticals Provides Update on Litigation with Belcher Pharmaceuticals

    Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that Adamis and Belcher Pharmaceuticals, LLC (“Belcher”) agreed to settle all previously filed litigation between the parties, including the case filed by Adamis in the United States District Court for the Middle District of Florida in which Adamis was seeking a declaratory judgment of non-infringement of certain patents in which Belcher claimed rights, relating to certain methods of preparing epinephrine solutions (“Patent Case”), and the inter partes review proceeding filed by Adamis in the United States Patent and Trademark Office requesting a formal review the validity of certain aspect of Belcher’s patents (“IPR”).

  • GlobeNewswire

    Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc.

    Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy. The company’s SYMJEPI™ (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products are FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.  Adamis is developing additional products, including the company’s ZIMHI™ naloxone injection product candidate for the treatment of opioid overdose, and a metered dose inhaler and dry powder inhaler product candidates for the treatment of asthma and COPD.  The company’s subsidiary, U.S. Compounding, Inc., compounds sterile prescription drugs and certain nonsterile drugs for human and veterinary use, to patients, physician clinics, hospitals, surgery centers and other clients throughout most of the United States.

  • GlobeNewswire

    Adamis Pharmaceuticals Provides Update on U.S. Retail Launch of SYMJEPI

    SAN DIEGO, July 09, 2019 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) provided an update that Sandoz Inc. (Sandoz), a Novartis division, today announced the U.S. retail.

  • Reuters

    Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage

    A unit of Novartis AG said on Tuesday it would make partner Adamis Pharmaceuticals Corp's emergency allergy shots immediately available in local pharmacies across the United States, amid a shortage of Mylan NV's rival product, EpiPen. The Sandoz unit of Novartis launched Symjepi for use in hospitals in January and had said it would make the treatment available in pharmacies in a phased manner. Mylan dominates the market for emergency allergy shots with EpiPen, an auto-injector that delivers a dose of epinephrine in the event of severe allergic reactions to a number of triggers, including bee stings or peanuts.

  • Have Insiders Been Selling Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Shares?
    Simply Wall St.

    Have Insiders Been Selling Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • GlobeNewswire

    Adamis Pharmaceuticals Provides Update on Its Higher Dose Naloxone Injection Product

    SAN DIEGO, June 11, 2019 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the receipt of.

  • GlobeNewswire

    Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product

    SAN DIEGO, May 21, 2019 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that on May 20, 2019, it received notice that it had been named and served as a.

  • GlobeNewswire

    Adamis Pharmaceuticals Announces Conditional Acceptance by FDA of Proprietary Name for Higher Dose Naloxone Product

    Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today conditional acceptance by the U.S. Food and Drug Administration (FDA) of the proposed brand name for the company’s high dose naloxone product candidate. The notification to the company from the FDA noted that after review, the proposed proprietary name “Zimhi™” was conditionally acceptable. Naloxone is an opioid antagonist used to treat narcotic overdoses.  Naloxone, which is generally considered the drug of choice for immediate administration for opioid overdose, blocks or reverses the effects of the opioid, including extreme drowsiness, slowed breathing, or loss of consciousness. Common opioids include morphine, heroin, tramadol, oxycodone, hydrocodone and fentanyl.

  • Thomson Reuters StreetEvents

    Edited Transcript of ADMP earnings conference call or presentation 9-May-19 9:00pm GMT

    Q1 2019 Adamis Pharmaceuticals Corp Earnings Call

  • Adamis Pharmaceuticals (ADMP) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    Adamis Pharmaceuticals (ADMP) Reports Q1 Loss, Misses Revenue Estimates

    Adamis (ADMP) delivered earnings and revenue surprises of -11.76% and -17.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    Adamis: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 19 cents. The biopharmaceutical company posted revenue of $4.9 million in the period. In the final minutes of trading on Thursday, ...

  • GlobeNewswire

    Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update

    On January 16, 2019, we announced that Sandoz had launched SYMJEPI™ (epinephrine) 0.3 mg Injection in the U.S. market. SYMJEPI will be rolled out via a phased launch and will initially be available in the institutional setting, an established channel where Sandoz has significant experience and knowledge, followed by anticipated introduction into the retail market. We also anticipate that Sandoz will launch the lower dose SYMJEPI (epinephrine) 0.15 mg Injection product in the U.S. markets.  With the continued rollout of SYMJEPI into the retail market, the company anticipates that the revenue stream to Adamis will increase in future quarters.